Loading stock data…
Organon & Co (OGN)
$13.52-0.04 (-0.29%)
Market ClosedLast close Jul 24
Organon & Co.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Organon & Co. in the Healthcare sector is trading at $13.52 with a market capitalization of $3.5B. Wall Street consensus targets $11.25 (4 analysts), implying a -16.8% move over the next 12 months. The stock is currently near its 52-week high of $13.60, remaining 43.2% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply -16.8% downside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.46B↓ | $1.51B↓ | $1.60B↑ | $1.59B↑ | $1.51B |
| Gross Profit | $783.00M↑ | $741.00M↓ | $857.00M↓ | $874.00M↑ | $841.00M |
| Operating Income | $266.00M↑ | $217.00M↓ | $358.00M↑ | $326.00M↑ | $325.00M |
| Net Income | $146.00M↑ | -$205.00M↓ | $160.00M↑ | $145.00M↑ | $87.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internatio...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.53B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.44%
ROE
Elite ROE. Management converts capital into profit efficiently.
27.24%
Volume
Today's trading volume
3.82M
Recent News
Organon & Co. Shareholders Clear Sun Pharma Merger Deal
Shareholders of Organon & Co. (NYSE:OGN) approved the company’s proposed merger agreement with Sun Pharmaceutical Holdings USA, Inc. at a virtual special meeting held Wednesday, according to preliminary voting results announced during the meeting. The special meeting was convened solely to cons
Organon (OGN) Names A Canada Chief, Is The Stock Cheap?
Leadership change in Canada puts Organon (OGN) in focus Organon (OGN) is back on investors’ radar after Organon Canada appointed Dominic Bégin as President and Managing Director, a leadership move that could influence how the company prioritizes its Canadian growth plans. See our latest analysis for Organon. For context, Organon’s share price is US$13.52, with a 90 day share price return of 57.21% and an 86.74% year to date share price return. The 3 year total shareholder return has declined...
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Can Organon & Co. (OGN)’s MIUDELLA Launch Become a Major Driver in Women’s Health Markets?
We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. Organon & Co. (NYSE:OGN) is one of the best low-priced pharma stocks on this list. TheFly reported on June 22 that OGN announced the completion of a global licensing agreement with Sebela Pharmaceuticals, securing exclusive rights to MIUDELLA, a hormone-free copper […]